Trials / Withdrawn
WithdrawnNCT04282239
Pectoral Nerves Block to Relieve Post-sternotomy Pain After Cardiac Surgery
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- NYU Langone Health · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine if the addition of PECS2 block provides superior post-operative analgesia for cardiac surgery patients after midline sternotomy compared to only standard-of-care post-operative pain medication.
Detailed description
The current study is a prospective, double-blind study investigating the use of pectoral nerves (PECS) block 2 to alleviate post-operative pain in cardiac surgery patients. The investigators anticipate enrolling a total of 220 participants in one of two groups, an interventional PECS block group and a control group not receiving the block. The intervention will occur in the operating room after the completion of the cardiac procedure and prior to the transfer of the participants to the cardiothoracic intensive care unit (CTICU). Both groups will receive the standard-of-care (SOC) pain regimen; the intervention with receive the PECS block in addition to SOC pain regimen. The procedure takes approximately five to ten minutes and will be conducted by the attending cardiac anesthesiologist. Pain will then be monitored hourly in the post-operative period in the CTICU. Additional measures will be investigated that are regularly logged in the electronic medical record.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | PECS2 block | Superficial peripheral nerve block placed at the interfascial plane between the pectoralis major and minor muscles and the plane between the pectoralis minor and serrates anterior muscles. Targeted nerves include the lateral and medial pectoral nerves in addition to the long thoracic nerve, thoracodorsal, and thoracic intercostal nerves from T2 to T6. |
| DRUG | Ropivacaine 0.5% Injectable Solution | 15 mL on each side of anterior chest for a total of 30mL |
| DRUG | Lidocaine Epinephrine | 10 mL on each side of anterior chest for a total of 20mL |
| DRUG | Dexmedetomidine 0.004 MG/ML | 10 mL |
Timeline
- Start date
- 2021-03-01
- Primary completion
- 2021-12-01
- Completion
- 2022-07-01
- First posted
- 2020-02-24
- Last updated
- 2021-12-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04282239. Inclusion in this directory is not an endorsement.